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Liver ﬁbrosis results from dysregulation of normal wound healing, inﬂammation, activation
of myoﬁbroblasts, and deposition of extracellular matrix (ECM). Chronic liver injury causes
death of hepatocytes and formation of apoptotic bodies, which in turn, release factors that
recruit inﬂammatory cells (neutrophils, monocytes, macrophages, and lymphocytes) to the
injured liver. Hepatic macrophages (Kupffer cells) produce TGFβ1 and other inﬂammatory
cytokines that activate CollagenType I producing myoﬁbroblasts, which are not present in
the normal liver. Secretion ofTGFβ1 and activation ofmyoﬁbroblasts play a critical role in the
pathogenesis of liver ﬁbrosis of different etiologies. Although the composition of ﬁbrogenic
myoﬁbroblasts varies dependent on etiology of liver injury, liver resident hepatic stellate
cells and portal ﬁbroblasts are the major source of myoﬁbroblasts in ﬁbrotic liver in both
experimental models of liver ﬁbrosis and in patients with liver disease. Several studies have
demonstrated that hepatic ﬁbrosis can reverse upon cessation of liver injury. Regression of
liver ﬁbrosis is accompanied by the disappearance of ﬁbrogenic myoﬁbroblasts followed by
resorption of the ﬁbrous scar. Myoﬁbroblasts either apoptose or inactivate into a quiescent-
like state (e.g., stop collagen production and partially restore expression of lipogenic genes).
Resolution of liver ﬁbrosis is associated with recruitment of macrophages that secrete
matrix-degrading enzymes (matrix metalloproteinase, collagenases) and are responsible
for ﬁbrosis resolution. However, prolonged/repeated liver injury may cause irreversible
crosslinking of ECM and formation of uncleavable collagen ﬁbers. Advanced ﬁbrosis
progresses to cirrhosis and hepatocellular carcinoma. The current review will summarize
the role and contribution of different cell types to populations of ﬁbrogenic myoﬁbroblasts
in ﬁbrotic liver.
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INTRODUCTION
PATHOGENESIS OF LIVER FIBROSIS
Hepatic ﬁbrosis is the outcome of many chronic liver diseases,
including cholestatic liver diseases [primary sclerosing cholangi-
tis (PSC), primary biliary cirrhosis (PBC), and secondary biliary
cirrhosis (SBC)], and hepatotoxic liver diseases [hepatitis B virus
(HBV), hepatitis C virus (HCV), alcoholic liver disease (ALD),
and non-alcoholic steatohepatitis (NASH); Bataller and Brenner,
2005]. It is characterized by extensive deposition of extracellular
matrix (ECM), including collagen Type I (Bataller and Bren-
ner, 2005; Kisseleva and Brenner, 2007; Kisseleva and Brenner,
2008a,b, 2011). Hepatic ﬁbrosis is caused by deregulation of phys-
iological wound healing, and results in excessive production of
ECM, mostly collagen type I, and scar formation. Activation
of collagen producing myoﬁbroblasts is critical for the patho-
genesis of liver ﬁbrosis (Bataller and Brenner, 2005; Kisseleva
and Brenner, 2008b). Studies of animal models of liver ﬁbrosis
Abbreviations: α-SMA, α-smooth muscle actin; aHSCs, activated HSCs; BDL, bile
duct ligation; BM, bone marrow; CCl4; carbon tetrachloride; ECM, extracellular
matrix; EMT, epithelial-to-mesenchymal transition; HCC, hepatic cellular carci-
noma; HSCs, hepatic stellate cells; iHSCs, inactivated HSCs; KC, Kupffer cells; LPS,
lipopolysaccharide; PF, Portal ﬁbroblast, qHSCs, quiescent HSCs.
and patient material have demonstrated that activation of hep-
atic myoﬁbroblasts plays a critical role in development of liver
ﬁbrosis. Increased number of myoﬁbroblasts correlates with the
severity of liver ﬁbrosis in patients (Brenner et al., 2012). There-
fore, myoﬁbroblasts became an attractive target for anti-ﬁbrotic
therapy aimed to eliminate the source of activated hepatic myoﬁ-
broblasts (Kisseleva et al., 2012; Liu et al., 2013). Myoﬁbroblasts
upregulate expression of α smooth muscle actin (α-SMA), non-
muscle myosin, ﬁbronectin, and exhibit stellate-like morphology.
Myoﬁbroblasts produce and secrete Collagen type I, the main
component of the ﬁbrous scar, and therefore, serve as a major
source of ECM (Eyden, 2008; Watsky et al., 2010; Brenner et al.,
2012). Although all myoﬁbroblasts share common characteriza-
tions (such as expression of Col1α1, α-SMA, TGFβRI, TIMP1,
PAI-1, activin, vimentin, ﬁbronectin, activation of TGFβ1 signal-
ing pathway), myoﬁbroblasts may originate from distinct cellular
sources, and the composition of myoﬁbroblast population may
vary dependent on the etiology of liver ﬁbrosis. Identiﬁcation
of the cellular source(s) of ﬁbrogenic myoﬁbroblasts provides
an invaluable insight into the pathophysiology of ﬁbrogenic liver
injury of different etiologies. Based on extensive studies, three
cellular populations mainly contribute to hepatic myoﬁbroblasts
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in response to chronic liver injury: hepatic stellate cells (HSCs;
Kisseleva and Brenner, 2006, 2007), portal ﬁbroblasts (PFs; Dra-
noff and Wells, 2010), and bone marrow (BM)-derived collagen
producing cells (ﬁbrocytes; Kisseleva et al., 2006; Scholten et al.,
2011; Iwaisako et al., 2012; Kisseleva and Brenner, 2012). Activated
HSCs (aHSCs) are the major source of myoﬁbroblasts in chronic
toxic liver injury (HBV, HCV infection, ALD, and NAFLD). PFs
were implicated in injury caused by cholestic liver injury (primary
and secondary biliary ﬁbrosis; Bataller and Brenner, 2005). The
role of ﬁbrocytes in liver ﬁbrosis remains unresolved. Recruitment
of BM-derivedﬁbrocytes into the injured liverwas observed in ani-
mal models of both toxic and cholestatic liver ﬁbrosis. However,
contribution of ﬁbrocytes to collagen producing myoﬁbroblasts
remains controversial. Identiﬁcation of the origin of myoﬁbrob-
lasts plays a critical role in understanding the pathogenesis of liver
ﬁbrosis.
CELL FATE MAPPING OF HEPATIC MYOFIBROBLASTS
Exploitation of Cre-LoxP systems in mice provided new opportu-
nities for cell fate mapping and lineage tracing of myoﬁbroblasts
of different origins (Gilbertson, 2003; Kisseleva et al., 2012). This
technique is based on cell-speciﬁc expression of Cre recombi-
nase (overexpressed under cell/lineage-speciﬁc promoter) in mice.
Upon crossing of Cre-expressing mice with reporter mice, such as
Rosa26-ﬂox-Stop-ﬂox-YFP mice, in which ﬂox-Stop-ﬂox codon
is knocked into Rosa26 locus, speciﬁc lineages of myoﬁbroblasts
and their progeny can be visualized and traced by expression of a
ﬂuorescent protein such as GFP or YFP.
ORIGIN OF HEPATIC MYOFIBROBLASTS
Several sources of hepatic myoﬁbroblasts have been identiﬁed
(Kalluri and Neilson, 2003; Kisseleva and Brenner, 2006; Fallow-
ﬁeld et al., 2007; Gomperts and Strieter, 2007). HSCs and PFs are
the liver resident mesenchymal cells (Asahina et al., 2009), they
activate and proliferate in response to injury, and are believed to
be the major source of myoﬁbroblasts in ﬁbrotic liver (Bataller
and Brenner, 2005; Kisseleva et al., 2006, 2011; Parola et al.,
2008; Roderfeld et al., 2009; Scholten et al., 2011). BM-derived
ﬁbrocytes and mesenchymal progenitor cells are recruited to the
injured liver and becomemyoﬁbroblasts (Bucala et al., 1994; Russo
et al., 2006). Hepatic epithelial cells may undergo a transition
into mesenchymal cells to contribute to the pathogenesis of liver
ﬁbrosis.
HEPATIC STELLATE CELLS
Hepatic stellate cells are liver resident cells that originate from
embryonic mesenchyme, and in adult healthy liver constitute
approximately 10% of total liver cells. Under physiological condi-
tions, HSCs exhibit a quiescent phenotype and serve as a major
storage of Vitamin A. Quiescent HSCs (qHSCs) are located in
the space of Disse (designated space between hepatocytes and
sinusoidal endothelial cells), store retinoids in lipid droplets, and
express desmin, neural markers, such as glial ﬁbrillar associated
protein (GFAP), synaptophisin, synemin, and nerve growth fac-
tor receptor p75 (Geerts, 2001; Bataller and Brenner, 2005). In
addition, Nr1d2, Adipor1, Adpf, Dbp, Prei4, and Foxj1 were iden-
tiﬁed as uniquemarkers associatedwithHSC quiescent phenotype
(Liu et al., 2013). In response to ﬁbrogenic liver injury and release
of TGFβ1, qHSCs rapidly undergo activation. They downreg-
ulate Vitamin A-containing lipid droplets and neural markers,
and differentiate into collagen Type I and αSMA-expressing
aHSCs/myoﬁbroblasts (Bataller and Brenner, 2005; Forbes and
Parola, 2011). They also upregulate production of matrix metallo-
proteinases MMPs, especially MMP13, and their inhibitors TIMPs
(Uchinami et al., 2006). Activation of HSCs is triggered mostly
by increased hepatic levels of proﬁbrogenic TGFβ1. In addition,
PDGF, FGF, and CTGF also induce HSC activation (Pinzani and
Marra, 2001; Reif et al., 2003; Hao et al., 2013). Recent studies have
demonstrated that IL-6, leptin, and IL-17A can also trigger HSC
activation (Bethanis and Theocharis, 2006; Michalopoulos, 2007;
Meng et al., 2012). In addition aHSCs upregulate Crlf1, Spp1,
Lox, LoxL2, IL-17Ra, Fosl1, and Folr1, genes that are uniquely
associated with aHSC phenotype (Liu et al., 2013).
Transgenic mice to study HSCs
Reporter Collagen-α1(I)-GFP (Col-GFP) mice (Yata et al., 2003)
are widely used to study activation of myoﬁbroblasts in many
types of organ ﬁbrosis. Expression of GFP driven by Collagen-
α1(I) promoter/enhancer (Yata et al., 2003) in these mice closely
correlates with expression of Collagen Type I protein (Magness
and Brenner, 1999; Magness et al., 2004), which is a major com-
ponent of the ﬁbrous scar (Bataller et al., 2003). These mice have
been extensively characterized and have become a standard tool to
visualize myoﬁbroblasts contributing to ﬁbrosis in liver, lungs,
kidneys, and skin (Brenner et al., 1989; Stefanovic et al., 1997,
2000, 2002, 2005; Stefanovic and Brenner, 2003; Kisseleva et al.,
2006, 2011; De Minicis et al., 2007; Lin et al., 2008; Taura et al.,
2008, 2010; Österreicher et al., 2011; Inokuchi et al., 2011; Par-
sons et al., 2011; Scholten et al., 2011; Meng et al., 2012; Meurer
et al., 2013). Using the Col-GFP mice we have recently demon-
strated that aHSCs [isolated by ﬂow cytometry as GFP+, Vitamin
A+,and Desmin+ cells (Friedman et al., 1985; Bataller and Bren-
ner, 2005; Seki et al., 2007)] comprise >92% of myoﬁbroblasts
in response to CCl4 (Kisseleva et al., 2012). Furthermore, sig-
niﬁcant progress has recently been made in the understanding
of HSC biology based on HSC cell fate mapping. For this pur-
pose, aHSCs were irreversibly labeled in CCl4-injured mice using
Col1α1-Cre mice, Col1α2-Cre mice, and inducible Col1α1-ERCre
mice. This technique allowed not only to trace and isolate aHSCs
from a pool of non-parenchymal cells using ﬂow cytometry-based
cell sorting technique, but also to determine their cellular fate
during regression of liver ﬁbrosis (Kisseleva and Brenner, 2008a;
Troeger et al., 2012). Hence, utilization of Cre expressing mice,
in which Cre expression is driven by collagen Type I promoter,
results in labeling of all hepatic myoﬁbroblasts. Therefore, sev-
eral successful attempts were made to generate HSC-speciﬁc Cre
mice. Thus, vimentin-ERCre mice have recently been reported to
label aHSCs (Troeger et al., 2012), while lecithin-retinol acyltrans-
ferase (Lrat)-ERCre mice induce tamoxifen-inducible Cre-LoxP
recombination in HSCs independent of the status of their activa-
tion (Mederacke et al., 2013). Off note, previous attempts at HSC
fate tracing have utilized hGFAP-Cre mice, however this yielded
rather controversial results, since hepatic Cre-LoxP recombination
in thesemice generated three different phenotypes: recombination
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in HSCs (Kisseleva and Brenner, 2008a; Krizhanovsky et al., 2008;
Lujambio et al., 2013), in cholangiocytes (Mederacke et al., 2013),
or in both HSCs and cholangiocytes (Yang et al., 2008).
Reversibility of liver ﬁbrosis
Many studies have clearly demonstrated that hepatic ﬁbrosis is
reversible in patients (e.g., HBV, HCV, biliary obstruction, or
alcohol) and in experimental rodent models (alcohol feeding,
CCl4, or bile duct ligation; Kisseleva and Brenner, 2011). Upon
removal of the etiological source of the chronic injury, regres-
sion of liver ﬁbrosis is associated with decreased cytokines and
ECM production, increased collagenase activity, disappearance
of myoﬁbroblast population and dissolution of the ﬁbrous scar
(Iredale et al., 1998; Bataller and Brenner, 2005). Only recently
has the fate of these myoﬁbroblasts been revealed. The previ-
ous concept was that the myoﬁbroblasts undergo apoptosis on
the basis of documented senescence during reversal of ﬁbrosis.
We (Kisseleva et al., 2012) and subsequently others (Troeger et al.,
2012) have used genetic marking to demonstrate an alternative
pathway in which myoﬁbroblasts revert to a quiescent-like pheno-
type in CCl4-induced liver injury and experimental ALD. Genetic
marking of myoﬁbroblasts enabled the quantitative mapping of
the fate of these cells in experimental models of ﬁbrosis and its
reversal.
Inactivation of HSCs
The mechanism of HSC activation is well understood, but very lit-
tle is known about HSC biology in the post-ﬁbrosis phase. Using
the Cre-LoxP-based genetic labeling of myoﬁbroblasts, the fate
of HSCs/myoﬁbroblasts during recovery from CCl4-induced liver
ﬁbrosis has been elucidated, and it has been demonstrated that half
of myoﬁbroblasts undergo senescence (Krizhanovsky et al., 2008)
and apoptosis (Iredale et al., 1998; Iredale, 2001), while half escape
apoptosis during regression of liver ﬁbrosis, downregulate ﬁbro-
genic genes and acquire a phenotype similar to, but distinct from,
qHSCs (Kisseleva et al., 2012). In particularly, iHSCs more rapidly
reactivate into myoﬁbroblasts in response to ﬁbrogenic stimuli
and more effectively contribute to liver ﬁbrosis. Inactivation of
HSCs is associated with re-expression of lipogenic genes PPAR-γ,
Insig1, and CREBP (She et al., 2005). Our ﬁndings in mice sup-
port the in vitro studies demonstrating the importance of PPAR-γ
for the maintenance of quiescent phenotype (qHSCs; Gaca et al.,
2003; She et al., 2005; Tsukamoto, 2005a,b; Wells, 2008). Follow-
ing regression of liver ﬁbrosis, HSCs restore their cellular mass and
Vitamin A storage.
It remains unclearwhy some aHSCs apoptose during regression
of liver ﬁbrosis, and some aHSC inactivate (Kisseleva et al., 2012).
Gene expression proﬁling of HSCs have demonstrated that those
HSCs that survive and inactivate strongly upregulate Hsp1a/b heat
shock proteins. Hsp1a/b proteins belong to Hsp70 family of heat
shock proteins, but are expressed only in certain cell types in
response to stress. We have demonstrated that Hsp1a/b knockout
HSCs are more susceptible to glyotoxin or TNFa-induced apop-
tosis. In addition, regression of liver ﬁbrosis in Hsp1a/b−/− is
accompanied by massive apoptosis of aHSCs, suggesting that these
two proteins may be involved in inactivation of HSCs (Kisseleva
et al., 2012).
Epigenetic regulation
Understanding the mechanisms of HSC inactivation during
regression of liver ﬁbrosis is critical for ﬁnding new targets for
anti-ﬁbrotic therapy. Inactivation of HSCs is most likely reg-
ulated at an epigenetic level (versus genetic mutations; Mann
et al., 2010; Tsukamoto et al., 2011). Epigenetics are heritable
changes in gene function that occur without a change in the
DNA sequence (Pepke et al., 2009). These changes, including
nucleosome dynamics and histone modiﬁcations, cause structural
alterations in the chromatin structure, and greatly affect gene
expression. Post-translational modiﬁcations of the core histone
subunits of nucleosomes are a fundamental mechanism by which
the transcriptional activity of an associated gene locus can be regu-
lated by methylation, acetylation, and phosphorylation (Henikoff,
2008; Park, 2009; Heinz and Glass, 2012). DNA methylation of
genes expressed in qHSCs probably contributes to the mainte-
nance of the quiescent phenotype. Upon activation, HSCs express
DNA methyl-binding proteins (MeCP2) that promote silencing
of antiﬁbrogenic genes, such as IkB-α or PPAR-γ, and increase
the expression of histone methyl transferase, leading in turn to
enhanced transcription of collagen, TIMP-1, and TGF-β. PPARγ
expression is associated with the adipogenic features of qHSC
and must be silenced for the cell to activate into myoﬁbroblasts
(Hazra et al., 2004; She et al., 2005; Tsukamoto et al., 2012; Yang
et al., 2012). A novel multi-step epigenetic network that con-
trols activation of HSCs in the injured liver has recently been
described, and involves activationof MeCP2 that causes alterations
at the H3K27 methylation sites and generates transcriptionally
repressed chromatin structure in the PPARγ promoter (She et al.,
2005; Mann et al., 2010). Consistently, overexpression of PPARγ in
aHSCs/myoﬁbroblasts in vitro results in reversion of HSC activa-
tion, and reacquisition of their adipogenic characteristics (Hazra
et al., 2004; Jaster et al., 2005).
The origin of HSCs
Hepatic stellate cells are believed to originate from mesenchymal
cells during embryogenesis and recovery from liver injury (Cas-
siman et al., 2002; Bataller and Brenner, 2005). However, several
important questions regarding HSC biology remain unknown.
For example, what is the half-life of HSCs? What cell type(s) give
rise to HSCs during liver organogenesis and in the adult liver?
Finally, what triggers HSC proliferation during activation of liver
ﬁbrosis? HSCs share characterizations of both neural cells (expres-
sion of astrocyte marker GFAP, nestin and p75Ntr; Geerts, 2001),
and mesodermal cells (smooth muscle marker desmin, adipocyte
characterization, and ability to transdifferentiate into myoﬁbrob-
lasts). Cell fate mapping of Wnt+ cells (using Wnt1-Cre mice
x Rosa-ﬂox-Stop-ﬂox-YFP mice) have demonstrated that HSCs
do not originate from neural crest precursors which derive to all
astrocytes (Cassiman et al., 2006). In turn, using lineage tracing of
MesP1+ cells Asahina et al. (2011)have demonstrated that HSCs
and PFs originate from mesenchymal precursors. In response to
injury HSCs proliferate and activate into myoﬁbroblasts. Cell fate
mapping of aHSCs [Collagen-a1(I)-Cre mice x Rosa-ﬂox-Stop-
ﬂox-YFP mice] have revealed that upon cessation of liver injury
aHSCs either apoptose or inactivate into a quiescent-like state
(Kisseleva et al., 2012). Interestingly, along with inactivated HSCs,
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which are genetically labeled and can be identiﬁed by YFP expres-
sion, we observed an emerging population of new HSCs without
the “history” of collagen expression (Kisseleva et al., 2012). New
studies are required to identify the source of HSCs in adult liver.
PORTAL FIBROBLASTS
Portal ﬁbroblasts reside underneath of the bile duct epithe-
lium and are the major myoﬁbroblast source in biliary cirrhosis,
which is caused by biliary obstruction (Clouzeau-Girard et al.,
2006; Dranoff and Wells, 2010). Biliary cirrhosis is character-
ized by dysregulated cholangiocyte proliferation and bile ductular
enlargement (Jhandier et al., 2005). Although PFs are the ﬁrst
“responders” to liver injury caused by biliary obstruction (Wells
et al., 2004), HSCs (and to lesser extend ﬁbrocytes) also con-
tribute to myoﬁbroblast populations with the disease progression
(Goddard et al., 1998).
Deﬁnition of PFs
Portal ﬁbroblasts are a heterogeneous population and represent
one of several ﬁbroblast populations in the liver. The term “portal
ﬁbroblast” refers to any ﬁbroblast in the portal region, and the
term “portal myoﬁbroblast” to any myoﬁbroblast that originates
in the portal area and is not derived from HSCs (Wells, 2014).
Therefore, here we deﬁne aPFs as ﬁbroblasts expressing ﬁbulin 2,
elastin, Thy1, interleukin 6, and the ectonucleotidase NTPDase
2, and do not express markers of stellate cells (Chapman and
Eagles, 2007). There are other ﬁbroblasts surrounding the cen-
tral vein (second layer cells) and in the liver capsule (Bhunchet
and Wake, 1992; Chapman and Eagles, 2007), many of which are
derived from a common mesothelial or submesothelial progenitor
cell that also gives rise to HSCs (Asahina et al., 2011). These pop-
ulations have not been well deﬁned or studied, and little is known
about their contribution to ﬁbrosis, epithelial maintenance, and
other functions essential to the health of the liver and bile
ducts.
Activation of PFs
Under physiological conditions, PFs comprise a small popula-
tion of cells that surround the portal vein to maintain integrity
of the portal tract (Dranoff and Wells, 2010). Activated PFs
(aPFs) are implicated in the pathogenesis of cholestatic liver injury
(Desmouliere et al., 1997), in which they proliferate and differen-
tiate into α-SMA-expressing myoﬁbroblasts that synthesize ECM
(Desmouliere et al., 1997; Yata et al., 2003; Dranoff and Wells,
2010). The contribution of aPFs to liver ﬁbrosis of different eti-
ologies is not well understood, mainly because of the difﬁculties
involved with the isolation of PFs and myoﬁbroblasts. The most
widely used method of aPF isolation from rat liver is based on
enzymatic digestion followed by size selection (Wen et al., 2012).
Cell outgrowth from dissected bile segments is still used to iso-
late rat PFs (Uchio et al., 2002), and after 10–14 days in culture
PFs undergo progressive myoﬁbroblastic differentiation (Kruglov
et al., 2002). Unfortunately, this technique has several disadvan-
tages since it requires multiple passaging and prolonged culturing
which change the original phenotype of the cells (Dranoff and
Wells, 2010). A more physiological method of studying PFs is
precision-cut liver slices (PCLS), designed to maintain cell–cell
and cell–matrix interactions and mimic the natural microenvi-
ronment of PFs, but this does not enable the study of puriﬁed
populations of PFs. Only a few markers are available to iden-
tify PFs in the myoﬁbroblast population, including gremlin, Thy1
(Knittel et al., 1999; Dudas et al., 2007; Yovchev et al., 2009), ﬁbu-
lin 2 (Knittel et al., 1999), IL-6, elastin (Goodpaster et al., 2008),
the ecto-AT-Pase nucleoside triphosphate diphosphohydrolase-2
(NTPD2; Dranoff et al., 2002), and cofﬁlin 1 (Bosselut et al., 2010).
aPFs may also upregulate intermediate ﬁlament vimentin, the col-
lagen receptor DDR2, and the calcium-binding protein S100A4
(Fsp1), and exhibit reactivity to the monoclonal antibody TE-7.
In addition, the lack of desmin, cytoglobin, β2-macroglobulin,
and Hand2, GFAP, p75NGFr, and Vitamin A distinguishes PFs
from HSCs (Bataller and Brenner, 2005; Dranoff and Wells, 2010;
Fausther andDranoff, 2011). Identiﬁcationof additional PFmark-
ers will advance our understanding of the pathogenesis of liver
ﬁbrosis.
Speciﬁc characteristics of aPFs
Two models of cholestatic liver injury are routinely used to study
activation of PFs in mice. Bile duct ligation is caused by surgi-
cal obstruction of the common bile duct and mimics cholestatic
liver disease in patients. Mice deﬁcient in the canalicular phos-
pholipid ﬂippase (Mdr2/Abcb4−/− mice) spontaneously develop
liver injury (PSC; Shimamura et al., 2008), (Fichtner-Feigl et al.,
2006; Jinnin et al., 2006; Fickert et al., 2009; Baghdasaryan et al.,
2010; Mair et al., 2010; McHedlidze et al., 2013), which resembles
PSC and most closely mimics MDR3 deﬁciency in patients,(Pope
et al., 2005) which ranges from familial intrahepatic cholestasis to
adult liver cirrhosis. The pathogenesis of liver injury in Mdr2−/−
mice is characterized by disruption of tight junctions and base-
ment membranes of bile ducts, bile leakage into the portal tract,
and formation of periportal biliary ﬁbrosis (Jinnin et al., 2006;
McHedlidze et al., 2013). aPFs were proposed to contribute to
ECM deposition in Mdr2−/− mice and in response to bile duct
ligation (Jinnin et al., 2006; Fickert et al., 2009). In the case of
cholestatic liver injury aPFs respond rapidly to increasing levels
of TGF-β1 (Liu et al., 2003) by upregulation of Col-α1(I), α-SMA,
TIMP1, TGF-β2 (Wells et al., 2004), PAI-1, elastin (Dranoff and
Wells, 2010), ﬁbronectin (Knittel et al., 1999; Ji et al., 2012), and
of CD73 ecto-enzyme (Li et al., 2007; Fausther et al., 2012; Ji et al.,
2012), and differentiate into collagen producing myoﬁbroblasts.
BDL-aPFs also secrete TGF-β1 and TGF- β2 (Wells et al., 2004).
FGF-2 facilitates activation of Pfs as well (Venkataraman et al.,
1999). Binding of FGF-2 to its tyrosine kinase receptors FGFRs,
and subsequent activation of Ras-MEK-Erk1/2 signaling causes
rapid proliferation and migration of aPFs (Itoh and Ohta, 2013).
Proliferation and activation of aPFs was shown to be blocked by
Curcumin, a non-steroidal yellow pigment found in rhizomes
of the perennial herb Curcuma longa, which blocks ERK1/2
phosphorylation in aPFs, and thus has a potential to reduce
cholestasis-induced ﬁbrogenesis (Baghdasaryan et al., 2010). aPFs
are believed to be the “ﬁrst responders” to cholestatic liver injury
which contribute to a signiﬁcant number of collagen producing
myoﬁbroblasts. aPFs begin to proliferate immediately after bile
duct ligation giving rise to a population of desmin-Vitamin A-
α-SMA+ myoﬁbroblasts adjacent to proliferating bile ducts and
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connective tissue stroma (Wells, 2014). Activation of PFs proceeds
activation and proliferation of HSCs, suggesting that activation of
HSCs is secondary to PFs in response to cholestatic liver injury
(Tuchweber et al., 1996; Desmouliere et al., 1997). In addition,
PFs play a role in maintenance of the peribiliary stem cell niche,
regulation of cholangiocyte proliferation, and deposition of spe-
ciﬁc matrix proteins, such as elastin and other components of
microﬁbrils, providing stability to ducts and the vasculature under
conditions of increased ductal pressure (Wells, 2014). Recent
studies have also proposed that HSCs and PFs occupy differ-
ent niches which yield myoﬁbroblasts with specialized functions
dependent on the etiology of liver injury. If the HSC niche is
activated in response to hepatotoxic damage and hypoxia to pro-
duce myoﬁbroblasts that mediate hepatocellular healing, then the
portal ﬁbroblast niche is activated by the ductular reaction to
produce PF–derived myoﬁbroblasts that regulate scar formation
(Lemoinne et al., 2013; Wells, 2014).
Origin of portal ﬁbroblast
Recent studies have suggested that during embryonic development
PFs, HSCs and vascular smooth muscle cells (VSMC) originate
from mesenchymal precursors of septum transversum (Suzuki
et al., 2008; Asahina et al., 2009). Lineage tracing of precursor cells
expressing mesodermal marker, MesP1Cre providesevidence that
septum transversum originates from mesoderm (Asahina et al.,
2011). At day 9.5 (E9.5) of mouse embryogenesis, when the hepatic
bile duct system and sinusoid start to form, septum transver-
sum is invaded by foregut endoderm. At E12.5, the perihepatic
membrane mesothelial cells and submesothelial cells give rise to
the mesenchymal cell precursors which invade into the liver mes-
enchyme (Asahina et al., 2011; Rinkevich et al., 2012). Several cell
markers of these mesenchymal cell precursors have been identi-
ﬁed, including Mesothelin, Desmin, p75NTR, Wt1, and ALCAM.
These mesenchymal precursors interact with endodermal hepa-
toblasts to induce the differentiation of hepatic parenchyma. It
remains unclear at which time point and speciﬁc stage of embry-
onic development PF and HSC precursors diverge from each other
and retain expression of cell speciﬁc markers throughout adult-
hood distinguishing these two cell types from each other. One
explanation which has evolved is that positioning during hepatic
lobule formation may designate functional specialization leading
to divergence of PFs from HSCs. In concordance, fetal PFs secrete
BMPs, Jagged1, and Hedgehog ligands to induce signaling criti-
cal for differentiation of hepatoblasts into cholangiocytes during
bile canaliculi and lumen formation (Dranoff and Wells, 2010;
Fabris and Strazzabosco, 2011), while fetal HSCs were implicated
in supporting proliferation of hepatoblasts by producing HGF,
pleiotrophin and FGF10 (Asahina et al., 2002; Berg et al., 2007).
FIBROCYTES
Bone marrow derived collagen producing Fibrocytes
Fibrocytes were ﬁrst described by Bucala et al. (1994), Bucala
(2008), and Grieb et al. (2011) and are deﬁned by the simulta-
neous expression of CD45 and collagen type I. Fibrocytes possess
dual characteristics of ﬁbroblasts (expression of collagen type I,
ﬁbronectin, and vimentin) and hematopoietic cells (CD45, CD34,
MHCII, CD11b, Gr1, Ly6c, CD54, CD80, CD86, CCR2, CCR1,
CCR7,CCR5;Abe et al., 2001; Quan et al., 2004). Under physiolog-
ical conditions, ﬁbrocytes have a spindle-like shape. In response to
injury (including liver injury), or stimulation by TGF-β, ﬁbrocytes
downregulate expression of hematopoietic markers and rapidly
differentiate intoα-SMA+ myoﬁbroblasts (Quan et al.,2004;Quan
and Bucala, 2007). Due to their ability to give rise to ﬁbrogenic
myoﬁbroblasts, ﬁbrocytes were implicated in the pathogenesis of
skin, lung, kidney, and liver ﬁbrosis (Phillips et al., 2004; Moore
et al., 2005, 2006; Kisseleva et al., 2006; Sakai et al., 2006; Ishida
et al., 2007; Strieter et al., 2007; Wada et al., 2007; Lin et al., 2008;
Grieb et al., 2011).
Approach to identify and study ﬁbrocytes in mice
We have developed a new functional method to distinguish
ﬁbrocytes from liver resident ﬁbrogenic myoﬁbroblasts (Kisseleva
et al., 2006; Higashiyama et al., 2009), or other BM-derived cells
(Scholten et al., 2010; Kisseleva et al., 2011). Based on the abil-
ity of a collagen-α1(I)-GFP transgene (Yata et al., 2003) to drive
GFP expression speciﬁcally in ﬁbrocytes, but not other cells of
the hematopoietic system [such as activated macrophages (Pilling
et al., 2009)], ﬁbrocyte-speciﬁc BM chimeric mice Col-GFP→wt
mice (generated by transplantation of Col-GFP BM into lethally
irradiated wild type recipient mice) became a useful tool to study
ﬁbrocyte biology. Liver injury causes rapid recruitment of BM-
derived ﬁbrocytes (Russo et al., 2006; Kallis and Forbes, 2009) to
ﬁbrotic livers of Col-GFP→wt mice. Using Col-GFP→wt mice,
we have identiﬁed that ﬁbrogenic liver injury activates several
populations of ﬁbrocytes, hepatic (Kisseleva et al., 2006), splenic
(Kisseleva et al., 2011), and BM CD45+Col+ ﬁbrocytes (Brenner
and Kisseleva, 2011; Scholten et al., 2011).
Fibrocytes contribute to liver ﬁbrosis
CD45+Col+ ﬁbrocytes migrate to the injured liver in response
to bile duct ligation (BDL, cholestatic injury) and comprise
≈4–6% of the collagen type I expressing cells (Kisseleva et al.,
2006). Similarly, ﬁbrocytes are recruited into CCl4-dameged liver
(Figures 1A,B), where they can differentiate into α-SMA+ myoﬁ-
broblasts in vivo (Scholten et al., 2011), suggesting that ﬁbrocyte
recruitment to the liver is a universal mechanism in the patho-
genesis of liver ﬁbrosis. In support, a signiﬁcant number of
ﬁbrocytes is recruited in Abcb4 knockout mice, a genetic model
of spontaneous liver ﬁbrosis. There was a signiﬁcant ﬂux of
ﬁbrocytes to the liver in these mice, such that ﬁbrocytes con-
tributed ≈50% to the liver myoﬁbroblast population (Roderfeld
et al., 2009). Although the mechanism of ﬁbrocyte recruitment
caused by this genetic deﬁciency is not completely understood, it
demonstrates that ﬁbrocytes have a strong potential to differenti-
ate intomyoﬁbroblasts under speciﬁc circumstances. For example,
adoptively transferred ﬁbrocytes that differentiate into collagen
producing cells when cultured on plastic, exacerbate pulmonary
ﬁbrosis in mice (Phillips et al., 2004). This phenomenon empha-
sizes ﬁbrocyte plasticity, ﬁbrogenic potential, and organ-speciﬁc
differentiation.
Migration of ﬁbrocytes to ﬁbrotic liver
Development of liver ﬁbrosis is mediated by increased secre-
tion of biologically active TGF-β1, intestinal lipopolysaccharide
(LPS) and pro-inﬂammatory chemokines CCL2, CCL7, CCL12,
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FIGURE 1 | Pathogenesis of liver fibrosis. (A) Hepatic lobular structure
under physiological conditions. Hepatic sinusoid, cholangiocytes and
hepatocytes, endothelial cells, hepatic stellate cells (HSCs) and portal
ﬁbroblasts (PFs), and Kupffer cells (KCs) are the components of hepatic
lobule. The bile duct, portal vein and hepatic artery form the portal triad. HSCs
are located in the space between hepatocytes and sinusoidal endothelium,
designated as the space of Disse. HSCs are considered as liver pericytes,
they contain lipid droplets and serve as the major storage of vitamin A. KCs
represent a population of hepatic macrophages. Only few ﬁbrocytes are
present in the healthy liver. (B) Changes in the hepatic lobule caused by
chronic liver injury. In response to chronic liver injury, hepatocytes undergo
apoptosis and release factors that recruit Kupffer cells, BM macrophages, and
ﬁbrocytes into the damaged liver. KCs, BM macrophages, and ﬁbrocytes
releaseTGFβ1, the most potent proﬁbrogenic cytokine, which activates HSCs
into collagenType I expressing myoﬁbroblasts. HSCs, PFs and, to a lesser
extent ﬁbrocytes, deposit extracellular matrix (ECM).
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and CCL3, which are the ligands for chemokine receptors CCR2
and CCR1 on hepatic and BM-derived cells (Seki et al., 2009a,b).
TGF-β1 triggers ﬁbrocyte mobilization into ﬁbrotic liver, suggest-
ing that regulation of ﬁbrocyte migration by TGF-β1 might be a
general characteristic of ﬁbrogenic injury of the liver and other
parenchymal organs (Phillips et al., 2004; Balmelli et al., 2007;
Hong et al., 2007). Moreover, recruitment of ﬁbrocytes from the
BM to the injured liver is regulated byCCR2 (Scholten et al., 2010),
a chemokine receptor that is also required for ﬁbrocyte migration
into ﬁbrotic lungs and kidneys (Phillips et al., 2004; Moore et al.,
2005; Sakai et al., 2006; Balmelli et al., 2007; Hong et al., 2007;
Ekert et al., 2011). Unlike lungs and kidneys (Phillips et al., 2004;
Moore et al., 2005, 2006; Sakai et al., 2006; Ishida et al., 2007; Wada
et al., 2007), recruitment of ﬁbrocytes to ﬁbrotic liver was shown
to be dependent on CCR1 (Scholten et al., 2010), indicating that
differential expression of chemokine receptors may determine an
organ-speciﬁc migration of ﬁbrocytes in response to ﬁbrogenic
injury.
BM is the source of hepatic ﬁbrocytes
Studies using bone marrow transplantation (BMT) in mice have
established that BM is the source of ﬁbrocytes. Under physiologi-
cal conditions ﬁbrocytes are primary located in the BM (comprise
0.1% of mononuclear cells), but proliferate and transmigrate
with the blood stream in response to injury (Quan et al., 2004).
Fibrocytes have been isolated from ﬁbrotic tissues, spleens and
peripheral blood (Bucala et al., 1994; Quan et al., 2004; Scholten
et al., 2011). BM-derived ﬁbrocytes have a spindle-like shape, but
in response to TGF-β1, they rapidly obtain a myoﬁbroblast pheno-
type (Quan et al., 2004). These BM ﬁbrocytes possess all classical
characteristic of ﬁbrocytes: expression of collagen, CD45, CD11b
CD34, Gr1, CD80, and CD86 (Quan et al., 2004; Bellini and Mat-
toli, 2007; Reilkoff et al., 2011). BM-derived ﬁbrocytes migrate
speciﬁcally into ﬁbrotic liver when adoptively transferred into
BDL mice (Scholten et al., 2011), supporting the notion that BM
ﬁbrocytes are a source of hepatic ﬁbrocytes/myoﬁbroblasts.
Development of liver injury is accompanied by recruitment of
ﬁbrocytes to the spleen
In addition to the injured organ, recruitment of CD45+Col+
ﬁbrocytes to the spleen has been documented during develop-
ment of liver (Kisseleva et al., 2006; Niedermeier et al., 2009) and
kidney ﬁbrosis (Sakai et al., 2006). Hepatotoxic injury (CCl4),
TGF-β1, LPS, or infection with Listeria monocytogenes (Lm) trig-
ger migration of ﬁbrocytes from the BM to the spleen and liver
(Kisseleva et al., 2011). Moreover, the spleen functions as a major
reservoir of immature ﬁbrocytes. Splenic CD45+Col+ ﬁbro-
cytes express myeloid markers and resemble CD115+CD11b+
monocytes (Kisseleva et al., 2011). Migration of ﬁbrocytes specif-
ically to Lm-infected spleen and liver indicate their potential
role in innate immunity. Although the biological signiﬁcance
of splenic ﬁbrocytes is not understood, our recent study sug-
gests that CD45+Col+ ﬁbrocytes are capable of differentiating
according to their microenvironment, giving rise to different
subtypes of ﬁbrocyte-like cells with distinct roles during tissue
repair and ﬁbrosis (Curnow et al., 2010). Consistent with this
observation, splenic ﬁbrocytes uniquely upregulate a variety of
antimicrobial factors [myleoperoxidase, cathelicidin (mCRAMP),
defensins; Kisseleva et al., 2011], and expression of MHC II
(Scholten et al., 2011). Although splenic ﬁbrocytes lack phagocytic
activity, they have developed alternative mechanisms to com-
bat infection. First, splenic ﬁbrocytes conﬁne bacterial spread
at the site of infection by entrapment of bacteria in extra-
cellular DNA-based structures (“DNA traps”; Kisseleva et al.,
2011), a mechanism previously identiﬁed only in neutrophils,
eosinophils, mast cells, and macrophages (Brinkmann et al.,
2004; von Kockritz-Blickwede et al., 2008; Youseﬁ et al., 2008;
Chow et al., 2010). Fibrocytes kill bacteria by secretion of cathe-
licidin into the DNA-based framework (Kisseleva et al., 2011).
Second, upon migration to the spleen, ﬁbrocytes strongly upreg-
ulate expression of MHC II (Scholten et al., 2011) and medi-
ate adaptive immunity by presenting antigens to naïve T cells
(Chesney et al., 1997; Balmelli et al., 2005) in vivo and in vitro
(Kisseleva et al., 2011). Although the antimicrobial properties
of ﬁbrocytes are aimed at stopping infection (Brinkmann and
Zychlinsky, 2007), release of nuclear DNA and lysosomal pep-
tides into the extracellular space facilitates inﬂammation, and
was shown to cause autoimmune vasculitis (Kessenbrock et al.,
2009).
EPITHELIAL MESENCHYMAL TRANSITION (EMT) AND LIVER FIBROSIS
The origin of myoﬁbroblasts from hepatic epithelial cells is
controversial. Although several evidence indicated that, under
prolonged in vitro culturing, hepatocytes and cholangiocytes
upregulate myoﬁbroblast marker aSMA and suppress epithelial
cellular marker (Kisseleva and Brenner, 2008a; Choi and Diehl,
2009; Kalluri, 2009), the fate mapping-based studies have clearly
demonstrated that hepatocytes and cholangiocytes, or their pre-
cursors do not undergo EMT in response to experimental models
of liver ﬁbrosis and do not give rise to myoﬁbroblasts (Scholten
et al., 2010; Chu et al., 2011; Österreicher et al., 2011). These
studies have shown that genetic labeling of hepatocytes (using
Albumin-Cre mice), cholangiocytes [using cytokeratin 19 (K-
19)-Cre mice] and their precursors did not yield generation of
myoﬁbroblasts in vivo. Furthermore, expression of S100A4 (Fsp1),
a marker which is associated with EMT progression, and widely
used to detect cells undergoing EMT, has been found to be
expressed not only by subsets of ﬁbroblasts but also by myeloid
cells, suggesting that the role of this protein in the pathogenesis of
liver ﬁbrosis has to be reevaluated.
HUMAN LIVER DISEASES AND FIBROGENIC CELL
POPULATIONS
It is well established that livermyoﬁbroblasts are the primary effec-
tor cells responsible for the extensive ECM accumulation and scar
formation observed during hepatic ﬁbrosis (Fausther et al., 2013).
Liver myoﬁbroblasts represent the critical targets for antiﬁbrotic
therapies, and therefore, it is important to determine the com-
position and contribution of distinct subsets of myoﬁbroblasts
to clinical and experimental liver ﬁbrosis of different etiologies
(Fausther et al., 2013). Based on the analysis of liver material
from patients with advanced ﬁbrosis and cirrhosis, three distinct
mesenchymal myoﬁbroblast-like liver cell subpopulations can be
discerned: portal/septal myoﬁbroblasts, interface myoﬁbroblasts
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and perisinusoidally located aHSCs. Septal myoﬁbroblasts share
more characteristics with portal myoﬁbroblasts than with HSCs
perhaps suggesting their common descent (Cassiman et al., 2002).
However, contribution of these subpopulations vary dependent
on underlying etiology of liver ﬁbrosis. Thus, primarily activation
of HSCs with upregulation of α-SMA is observed in patients with
viral hepatitis B and C (Giannelli and Antonaci, 2005; Friedman,
2008a,b). In addition, viral antigens anddsDNAare able to activate
HSCs via CD4/CD8 lymphocyte mediated manner (Enzan et al.,
1994; Muhanna et al., 2008). In cholestatic liver ﬁbrosis, both aPFs
and aHSCs contribute to the ECMdeposition, and themajor accu-
mulation of collagen expressing cells have been observed around
proliferating bile ducts (Goddard et al., 1998).
Recruitment of ﬁbrocytes in patients with liver ﬁbrosis has been
documented. The number of circulating ﬁbrocytes was shown to
correlate with the severity of ﬁbrosis induced by HCV (Bucala,
2008), lung ﬁbrosis (Strieter et al., 2009) and Crohn’s disease
(Sahebally et al., 2013), suggesting that ﬁbrocytes may serve as
a prognostic marker, and become a novel target for anti-ﬁbrotic
therapy in ﬁbrosis. However, the function of ﬁbrocytes in the
liver is not well understood. Thus, ﬁbrocytes were implicated to
be a major source of collagen Type I producing cells in patients
with nephrogenic systemic ﬁbrosis (NSF; Cowper and Bucala,
2003; Galan et al., 2006). Meanwhile, recent reports suggest that
ﬁbrocyte function is not limited to ECM deposition, and ﬁbro-
cytes also act to promote ﬁbrosis via paracrine actions, such as
secretion of growth factors, proteases, and matricellular proteins,
which affect resident epithelial and mesenchymal cells towards
pathologic remodeling (Kleaveland et al., 2014).
Although the data supporting the concept of EMT in adult
patients with liver ﬁbrosis has recently been critically questioned,
there is evidence that EMT occurs during mammalian embryo-
genesis and cancerogenesis. Therefore, it is quite possible that
pediatric patients who are born with biliary atresia may retain
a rudimentary mechanism by which bile ducts undergoing EMT
may account for prominent bile ductular proliferation and ﬁbro-
genesis (Deng et al., 2011). Liver sections frompatientswith biliary
atresia were evaluated to detect antigen for the BECs marker 4 and
cytokeratin-7 (CK-7), proteins (ﬁbroblast-speciﬁc protein 1, also
known S100A4; the collagen chaperone heat shock protein 47,
HSP47) characteristically expressed by cells undergoing EMT, as
well as myoﬁbroblast marker a-smooth muscle actin (a-SMA).
CONCLUSION
The composition of myoﬁbroblasts varies dependent on the etiol-
ogy of liver ﬁbrosis. Hence, liver resident HSCs and portal/septal
ﬁbroblasts are considered to be the major source of ﬁbrogenic
myoﬁbroblasts in the damaged liver and serve as primary targets
for anti-ﬁbrotic therapy. Speciﬁcally, recent studies on epigenetic
regulation of hepatic myoﬁbroblasts provide new opportunities
for drug discovery (Mann and Mann, 2009; Mann et al., 2010).
Furthermore, identiﬁcation of inactivated phenotype in HSCs,
suggests that aHSCs can be manipulated to stop producing colla-
gen and reverse to their quiescent like state. Unfortunately, much
less is known about PFs. Although activation of PFs is restricted
mostly to cholestatic liver injury, new tools are required to study
this population of mesenchymal cells contributing to liver ﬁbrosis.
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